BACKGROUND: The late durability of endovascular aneurysm repair (EVAR) has been limited by progressive aortic degeneration believed to be mediated by matrix metalloproteases (MMP). The goal of this study was to evaluate the effect of a MMP inhibitor, doxycycline, on EVAR. METHODS:Patients undergoing EVAR were randomized to doxycycline (100 mg twice daily) or placebo for 6 months following the procedure. Clinical data, blood samples, and computed tomography (CT) scans were obtained preoperatively, postoperatively (blood only), and at 1- and 6-month follow-up. Forty-four subjects were analyzed based on intention-to-treat. RESULTS:Plasma MMP-9 decreased significantly below baseline in the doxycycline (N = 20) treated patients at 6 months (-16.4% +/- 20.7%, P < .05) while there was a nonsignificant increase in the placebo (N = 24) group (128.1% +/- 73.5%). This was primarily related to changes between 1 and 6 months. In patients with endoleaks at 6 months, plasma MMP-9 increased in 83% of the placebo treated patients, but in only 14% of the doxycycline treated group (P < .03). Among endoleak-free patients with AneuRx or Excluder endografts, doxycycline treatment resulted in greater decreases in maximum aortic diameter than placebo treatment (-13.3% +/- 3.3% vs -3.8% +/- 3.0%, P < .05). Furthermore, doxycycline treatment significantly reduced the aortic neck dilatation at 6 months in Excluder treated patients. CONCLUSION: There is evidence of persistent MMP release representing ongoing aortic degradation after endografting which can be inhibited by doxycycline therapy. In analyses based on the endograft used, treatment with doxycycline also demonstrated evidence of increased aortic dimensional stability, a surrogate marker for long-term success of EVAR. Although encouraging, these results require confirmation in larger patient populations. Doxycycline should undergo more thorough evaluation as a potential adjuvant treatment to improve the results of EVAR, particularly in certain subgroups.
RCT Entities:
BACKGROUND: The late durability of endovascular aneurysm repair (EVAR) has been limited by progressive aortic degeneration believed to be mediated by matrix metalloproteases (MMP). The goal of this study was to evaluate the effect of a MMP inhibitor, doxycycline, on EVAR. METHODS:Patients undergoing EVAR were randomized to doxycycline (100 mg twice daily) or placebo for 6 months following the procedure. Clinical data, blood samples, and computed tomography (CT) scans were obtained preoperatively, postoperatively (blood only), and at 1- and 6-month follow-up. Forty-four subjects were analyzed based on intention-to-treat. RESULTS: Plasma MMP-9 decreased significantly below baseline in the doxycycline (N = 20) treated patients at 6 months (-16.4% +/- 20.7%, P < .05) while there was a nonsignificant increase in the placebo (N = 24) group (128.1% +/- 73.5%). This was primarily related to changes between 1 and 6 months. In patients with endoleaks at 6 months, plasma MMP-9 increased in 83% of the placebo treated patients, but in only 14% of the doxycycline treated group (P < .03). Among endoleak-free patients with AneuRx or Excluder endografts, doxycycline treatment resulted in greater decreases in maximum aortic diameter than placebo treatment (-13.3% +/- 3.3% vs -3.8% +/- 3.0%, P < .05). Furthermore, doxycycline treatment significantly reduced the aortic neck dilatation at 6 months in Excluder treated patients. CONCLUSION: There is evidence of persistent MMP release representing ongoing aortic degradation after endografting which can be inhibited by doxycycline therapy. In analyses based on the endograft used, treatment with doxycycline also demonstrated evidence of increased aortic dimensional stability, a surrogate marker for long-term success of EVAR. Although encouraging, these results require confirmation in larger patient populations. Doxycycline should undergo more thorough evaluation as a potential adjuvant treatment to improve the results of EVAR, particularly in certain subgroups.
Authors: G Sangiorgi; R D'Averio; A Mauriello; M Bondio; M Pontillo; S Castelvecchio; S Trimarchi; V Tolva; G Nano; V Rampoldi; L G Spagnoli; L Inglese Journal: Circulation Date: 2001-09-18 Impact factor: 29.690
Authors: J A Curci; D Mao; D G Bohner; B T Allen; B G Rubin; J M Reilly; G A Sicard; R W Thompson Journal: J Vasc Surg Date: 2000-02 Impact factor: 4.268
Authors: R Pyo; J K Lee; J M Shipley; J A Curci; D Mao; S J Ziporin; T L Ennis; S D Shapiro; R M Senior; R W Thompson Journal: J Clin Invest Date: 2000-06 Impact factor: 14.808
Authors: David R Lorelli; Jessie M Jean-Claude; Christopher J Fox; Jason Clyne; Robert A Cambria; Gary R Seabrook; Jonathan B Towne Journal: J Vasc Surg Date: 2002-05 Impact factor: 4.268
Authors: B Timothy Baxter; William H Pearce; Eugene A Waltke; Fred N Littooy; John W Hallett; K Craig Kent; Gilbert R Upchurch; Elliot L Chaikof; Joseph L Mills; Beverly Fleckten; G Matt Longo; Jason K Lee; Robert W Thompson Journal: J Vasc Surg Date: 2002-07 Impact factor: 4.268
Authors: Kenneth Ouriel; Daniel G Clair; Roy K Greenberg; Sean P Lyden; Patrick J O'Hara; Timur P Sarac; Sunita D Srivastava; Brett Butler; Ellis S K Sampram Journal: J Vasc Surg Date: 2003-05 Impact factor: 4.268
Authors: R W Thompson; D R Holmes; R A Mertens; S Liao; M D Botney; R P Mecham; H G Welgus; W C Parks Journal: J Clin Invest Date: 1995-07 Impact factor: 14.808
Authors: Roy K Greenberg; David Deaton; Timothy Sullivan; Esteban Walker; Sean P Lyden; Sunita D Srivastava; Kenneth Ouriel; Thomas Ivanc; Tamara Burton; Jason Mayo Journal: J Vasc Surg Date: 2004-01 Impact factor: 4.268
Authors: Michael S Conners; W Charles Sternbergh; Glen Carter; Britt H Tonnessen; Moises Yoselevitz; Samuel R Money Journal: J Vasc Surg Date: 2002-09 Impact factor: 4.268
Authors: Castigliano M Bhamidipati; Gaurav S Mehta; Guanyi Lu; Christopher W Moehle; Carlos Barbery; Paul D DiMusto; Adriana Laser; Irving L Kron; Gilbert R Upchurch; Gorav Ailawadi Journal: Surgery Date: 2012-08 Impact factor: 3.982
Authors: Lora Melman; Phillip R Chisholm; John A Curci; Batool Arif; Richard Pierce; Eric D Jenkins; L Michael Brunt; Christopher Eagon; Margaret Frisella; Kathleen Miller; Brent D Matthews Journal: Surg Endosc Date: 2010-01-07 Impact factor: 4.584
Authors: Vaidehi R Chowdhary; Cynthia S Crowson; Kimberly P Liang; Clement J Michet; Dylan V Miller; Kenneth J Warrington; Eric L Matteson Journal: Arthritis Res Ther Date: 2009-02-27 Impact factor: 5.156